Home › Compound Library › 6-APB (Benzofury / 6-(2-aminopropyl)benzofuran)

6-APB (Benzofury / 6-(2-aminopropyl)benzofuran)

Empathogenoral · inferred

Benzofuran analog of MDA with MDMA-like empathogenic/entactogenic effects and longer duration (8-10h). Triple monoamine releaser (SERT > NET > DAT) producing serotonin-dominant empathogenic effects. 5-HT2B agonism raises concern for cardiac valvulopathy with chronic use — a known risk of fenfluramine-class serotonergic drugs. CYP2D6 substrate. Sold as a "research chemical" and club drug; frequently misrepresented as MDMA. Longer onset (60-90 min) can lead to dangerous re-dosing.

Projected serum levels — 100 mg, as needed (shown daily)

6-APB (Benzofury / 6-(2-aminopropyl)benzofuran)
6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) modeled serum levels, 100 mg as needed (shown daily) over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 25 50 75 100 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 100 mg as needed (shown daily) (oral).

Modeled steady state after ~1 days: peak ≈ 62.3 mg, trough ≈ 11.2 mg body load. Population-based estimate over 15 days for a 100 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Empathogen
Route modeled
Oral
Model confidence
inferred
Half-life
8 h
Common dose
100 mg
Suggested maximum
150 mg/day
Reference dose range
50–150 mg (single dose)
Suggested cadence
as needed (shown daily)

Documented interactions

  • contraindicated
    MDA (3,4-Methylenedioxyamphetamine) + 6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) CYP inhibition

    MDA (3,4-Methylenedioxyamphetamine) mechanism_based of CYP2D6 predicted to change 6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) AUC by ~10.00x

  • contraindicated
    MDMA (Ecstasy) + 6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) CYP inhibition

    MDMA (Ecstasy) mechanism_based of CYP2D6 predicted to change 6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) AUC by ~10.00x

  • contraindicated
    Paroxetine (Paxil) + 6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) CYP inhibition

    Paroxetine (Paxil) mechanism_based of CYP2D6 predicted to change 6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) AUC by ~10.00x

  • danger
    1P-LSD (1-Propionyl-LSD) + 6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) Serotonin risk

    1P-LSD (1-Propionyl-LSD) and 6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental…

  • danger
    25I-NBOMe + 6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) Serotonin risk

    25I-NBOMe and 6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-I (2,5-Dimethoxy-4-iodophenethylamine) + 6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) Serotonin risk

    2C-I (2,5-Dimethoxy-4-iodophenethylamine) and 6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic…

Serum checks 117 modeled interaction pairings for 6-apb (benzofury / 6-(2-aminopropyl)benzofuran) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. 6-APB and other benzofurans — EMCDDA–Europol Joint Report on a new psychoactive substance EMCDDA · European Monitoring Centre for Drugs and Drug Addiction, 2014

    Formal EU risk assessment of 6-APB documenting its emergence as a "legal high" substitute for MDMA, its triple monoamine releaser pharmacology, and health risks including hyperthermia, serotonin syndrome, and…

  2. 6-APB — PsychonautWiki PsychonautWiki contributors · PsychonautWiki, 2024

    Community knowledge base documenting 6-APB subjective effects, dose ranges (light 30-60mg, common 60-90mg, strong 90-120mg, heavy 120-150mg), duration (8-10h), onset delay (60-90 min leading to redosing risk), and harm…

2 published studies referenced in the app, each with a plain-language summary.